AstraZeneca: 49% increase in quarterly core EPS

(CercleFinance.com) - AstraZeneca reports Q4 2024 total sales of $14.
89bn, up 24% as reported (+25% at constant exchange rates), with EPS of $0.97 (+56% as reported, +71% at constant exchange rates) and core EPS of $2.09 (+44% as reported, +49% at constant exchange rates).

AstraZeneca posted FY total sales of $54bn, up 18% (+21% at constant exchange rates), for EPS of $4.54 (+18% as reported, +29% at constant exchange rates) and core EPS of $8.21 (13% as reported, +19% at constant exchange rates).

Pleased with a very good performance in 2024, it reports that the laboratory has achieved "nine positive results in high-value Phase III studies during the year, which, combined with growing demand for our medicines in all key regions, will help maintain growth momentum in 2025.

As such, AstraZeneca expects total sales to rise by 'a high single-digit percentage' and core EPS to increase by 'a low double-digit percentage' in 2025.

Following this publication, the stock was up nearly 5% in London.


Copyright (c) 2025 CercleFinance.com. All rights reserved.